# OnCo record tnbc-residual-disease-decision (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/tnbc-residual-disease-decision/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "tnbc-residual-disease-decision" ;
  schema:name "Residual disease after neoadjuvant therapy in triple-negative breast cancer: the decision point"@en ;
  schema:alternateName "Non-pCR TNBC"@en, "Residual cancer burden after KEYNOTE-522"@en, "Post-neoadjuvant TNBC"@en ;
  schema:description "When triple-negative breast cancer is still present at surgery after pre-operative chemotherapy and pembrolizumab, the amount left (the residual cancer burden) is what decides the next treatment: a year of olaparib for inherited BRCA carriers, capecitabine for others, pembrolizumab to complete the year, and trials of antibody-drug conjugates for everyone else."@en ;
  schema:url <https://onco.cc/terms/tnbc-residual-disease-decision/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(21)00589-1>, <https://doi.org/10.1016/j.annonc.2024.02.002>, <https://doi.org/10.1056/NEJMoa1612645>, <https://doi.org/10.1056/NEJMoa2105215> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/adc/> ;
  onco:drugs <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/datopotamab-deruxtecan/> ;
  onco:terms <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/efs/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/de-escalation/>, <https://onco.cc/terms/gbrca-mutation/> ;
  onco:trials <https://onco.cc/trials/keynote-522/>, <https://onco.cc/trials/create-x/>, <https://onco.cc/trials/olympia/>, <https://onco.cc/trials/ea1131/>, <https://onco.cc/trials/bre12-158/>, <https://onco.cc/trials/swog-s1418/>, <https://onco.cc/trials/ascent-05/>, <https://onco.cc/trials/tropion-breast03/>, <https://onco.cc/trials/c-trak-tn/>, <https://onco.cc/trials/sysucc-001/>, <https://onco.cc/trials/geicam-ciboma/> .